複雑性尿路感染症に対するCefotetanの臨床的検討

概要

論文の詳細を見る
複雑性尿路感染症28例にCTTを投与した.1)総合臨床効果は著効12例(42.9%),有効10例(35.7%),無効6例(21.6%),総合有効率78.6%であった.2)治療前の分離細菌は10種32株で,24株(75%)の消失を示した.P. aeruginosaも10株中6株の消失がみられたが,S. faecalisとともに他菌種に比しやや低い消失率を示した.3) 1例で自覚的に,6例で臨床検査上に異常を示したが,薬剤投与中止後早期に回復したClinical effectiveness and safety of Cefotetan were evaluated in 28 patients with complicated urinary tract infections. The results were excellent in 12 patients (42.9%), moderate in 10 patients (35.7%) and poor in 6 patients (21.6%), and the effectiveness rate was 78.6%. Bacteriologically, 24 (75%) out of 32 strains were eradicated. Subjective side effects, nausea and abdominal discomfort, were observed in one patient. Abnormal laboratory findings were observed in 6 patients, eosinophilia in 3 patients and slight elevation of transaminase in 3 patients.